Abstract
Cancer cachexia is a complex syndrome clinically manifest by progressive involuntary weight loss and diminished food intake and characterized by a variety of biochemical alterations. Importantly, cancer cachexia has been associated with increased morbidity and mortality and decreased response to therapy. The impact of cancer cachexia on patient outcome and healthcare resources continues to be significant. It is therefore important to identify those cancer patients who are malnourished in an attempt to reverse or at least abate the progression of malnutrition. The goal of nutritional supplementation is to translate repletion into clinical benefit, thereby decreasing morbidity or mortality and increasing the response rate to treatment. The focus of this chapter is to review the etiology of cancer cachexia, summarize the biologic and clinical effects of nutrition, define specific indications for nutrition in the cancer patient population, and explore new therapies available to reverse cancer cachexia.
| Original language | English (US) |
|---|---|
| Title of host publication | Oncology |
| Subtitle of host publication | An Evidence-Based Approach |
| Publisher | Springer New York |
| Pages | 1497-1514 |
| Number of pages | 18 |
| ISBN (Print) | 0387242910, 9780387242910 |
| DOIs | |
| State | Published - Dec 1 2006 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
}
Nutritional support for the cancer patient. / Harrison, Lawrence.
Oncology: An Evidence-Based Approach. Springer New York, 2006. p. 1497-1514.Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Nutritional support for the cancer patient
AU - Harrison, Lawrence
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Cancer cachexia is a complex syndrome clinically manifest by progressive involuntary weight loss and diminished food intake and characterized by a variety of biochemical alterations. Importantly, cancer cachexia has been associated with increased morbidity and mortality and decreased response to therapy. The impact of cancer cachexia on patient outcome and healthcare resources continues to be significant. It is therefore important to identify those cancer patients who are malnourished in an attempt to reverse or at least abate the progression of malnutrition. The goal of nutritional supplementation is to translate repletion into clinical benefit, thereby decreasing morbidity or mortality and increasing the response rate to treatment. The focus of this chapter is to review the etiology of cancer cachexia, summarize the biologic and clinical effects of nutrition, define specific indications for nutrition in the cancer patient population, and explore new therapies available to reverse cancer cachexia.
AB - Cancer cachexia is a complex syndrome clinically manifest by progressive involuntary weight loss and diminished food intake and characterized by a variety of biochemical alterations. Importantly, cancer cachexia has been associated with increased morbidity and mortality and decreased response to therapy. The impact of cancer cachexia on patient outcome and healthcare resources continues to be significant. It is therefore important to identify those cancer patients who are malnourished in an attempt to reverse or at least abate the progression of malnutrition. The goal of nutritional supplementation is to translate repletion into clinical benefit, thereby decreasing morbidity or mortality and increasing the response rate to treatment. The focus of this chapter is to review the etiology of cancer cachexia, summarize the biologic and clinical effects of nutrition, define specific indications for nutrition in the cancer patient population, and explore new therapies available to reverse cancer cachexia.
UR - http://www.scopus.com/inward/record.url?scp=84892308076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892308076&partnerID=8YFLogxK
U2 - 10.1007/0-387-31056-8_84
DO - 10.1007/0-387-31056-8_84
M3 - Chapter
SN - 0387242910
SN - 9780387242910
SP - 1497
EP - 1514
BT - Oncology
PB - Springer New York
ER -